Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Aura Biosciences (AURA) Other financing activities (2020 - 2021)

Aura Biosciences filings provide 2 years of Other financing activities readings, the most recent being -$1.4 million for Q4 2021.

Quarterly Other financing activities fell 15800.0% to -$1.4 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$15000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at -$15000.0 for FY2021, 55.88% up from the prior year.
Other financing activities hit -$1.4 million in Q4 2021 for Aura Biosciences, down from $1.1 million in the prior quarter.
Across five years, Other financing activities topped out at $1.1 million in Q3 2021 and bottomed at -$1.4 million in Q4 2021.